MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced that the first patients have been dosed in a Phase II clinical trial of its lead drug candidate Pracinostat in combination with Vidaza (azacitidine) in patients with previously Result

read more>>

A genetically reprogrammed Herpes simplex virus can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study published January 31 in the Open Access journal PLOS PathogensThe paper reports on the collaborative research from scientists at the at th

read more>>

A new approach to reducing sickle cell anemia's painful attacks has entered Phase II clinical trialsThe drug, Lexiscan, is already approved for diagnosing heart disease. Scientists led by Joel Linden, a researcher at the La Jolla Institute for Allergy & Immunology, discovered that the drug might a

read more>>

Autism is an umbrella term for various complex disorders with most of their causes being poorly or not understood. This lack of current knowledge together with the fact that the number of affected people is rising makes the quest for potent treatments very difficult and urgentMany forms of autism

read more>>

It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In patients with these mutations, PARP inhibitors, which are currently in The t

read more>>

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancerThe aim of the collaboration between

read more>>

A mild form of the fragile X mutation produces an unusual protein that may trigger fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder, according to a study published 8 May in Neuron1Fragile X syndrome is caused by more than 200 repeats of three nucleotides (CGG) loca

read more>>

There seem to be two broad patterns of disease progression in autism. Many individuals with the disorder show features within the first year of life, with gradually developing impairments in social and language development1, 2However, a significant minority displays another distinct course, marked

read more>>

The mutation that causes tuberous sclerosis complex, an autism-related disorder, may disable calming signals in the brain, leading to hyperactive neurons, according to a study published 8 May in Neuron1Tuberous sclerosis is caused by mutations in either TSC1 or TSC2 and is characterized by benign

read more>>

Hyperion Therapeutics, Inc. announced that population pharmacokinetic (PK) modeling and dosing simulations were reported in The Journal of Clinical Pharmacology based on data from four Phase 2 and 3 trials that collectively enrolled patients with urea cycle disorders (UCDs) ages 2 months to 72 UCD

read more>>